Related Experiment Videos
Cord blood reverse T3 in congenital hypothyroidism
Insights
Reverse triiodothyronine (rT3) levels were lower in infants with congenital hypothyroidism. However, rT3 measurement in cord blood is not advantageous for newborn screening due to significant overlap with normal values.
Area of Science:
- Endocrinology
- Neonatal Medicine
- Biochemistry
Background:
- Congenital hypothyroidism (CH) is a treatable condition requiring early diagnosis.
- Newborn screening aims to detect CH promptly to prevent developmental issues.
- Reverse triiodothyronine (rT3) is a thyroid hormone with potential implications in neonatal thyroid status.
Purpose of the Study:
- To investigate the potential of reverse triiodothyronine (rT3) measurement in cord serum as a screening tool for congenital hypothyroidism.
- To compare rT3 levels in infants with CH against those in healthy newborns.
Main Methods:
- Measurement of rT3 concentrations in cord serum samples.
- Comparison of mean rT3 values between a cohort of infants with CH and a control group of euthyroid infants.
Main Results:
- Infants with congenital hypothyroidism exhibited significantly lower mean rT3 levels (135 +/- 12 ng/dl) compared to euthyroid controls (270 +/- 9 ng/dl).
- A substantial overlap in rT3 concentration ranges was observed between the CH group and the control group.
Conclusions:
- While mean rT3 levels are lower in infants with CH, the significant overlap precludes its use as a standalone screening method.
- Current newborn screening methods for congenital hypothyroidism remain superior to rT3 determination in cord blood.
Abstract:
Reverse triiodothyronine (rT3) was measured in cord serum from 5 infants with congenital hypothyroidism and compared with normal values in 70 euthyroid control infants. The mean (and SEM) value in the affected infants (135 +/- 12 ng/dl) was significantly lower than that in the control population (270 +/- 9 ng/dl). However, the large overlap in range of concentrations in affected and control infants indicates that newborn screening based on the determination of rT3 in cord blood specimens offers no advantage over present screening methods.